The NCMAG Council makes decisions on the proposed use of cancer medicines.
These medicines uses are planned for review by NCMAG:
NCMAG 126 – Nivolumab plus ipilimumab
For use as neoadjuvant treatment of mismatch repair deficient or microsatellite instability‑high locally advanced colon cancer which is judged to be borderline resectable. (off-label use)
- Council meeting date: 19 March 2026
- Planned publication date: 23 April 2026
NCMAG127 - Arsenic trioxide in combination with all-trans retinoic acid
For treatment of adults with high-risk acute promyelocytic leukaemia (APML). (off-label use and off-patent medicine)
- Council meeting date: 18 June 2026
- Planned publication date: 23 July 2026